Abstract:Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in awide variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells upon T cell activation. After engagement with its ligands, mainly PD-L1, PD-1 is activated and recruits the phosphatase SHP-2 in proximity to T cell receptor (TCR) and CD28 signaling. This event results in dephosphorylation and attenuation of key molecules in TCR and CD28 pathway, leading to inhibition of T cell proliferation, activation, cytokine production, altered metabolism and cytotoxic T lymphocytes (CTLs) killer functions, and eventual death of activated T cells. Bodies evolve coinhibitory pathways controllingTcell response magnitude and duration to limit tissue damage and maintain self-tolerance. However, tumor cells hijack these inhibitory pathways to escape host immune surveillance by overexpression of PD-L1. This provides the scientific rationale for clinical application of immune checkpoint inhibitors in oncology. The aberrantly high expression of PD-L1 in tumor microenvironment (TME) can be attributable to the "primary" activation of multiple oncogenic signaling and the "secondary" induction by inflammatory factors such as IFN-.. Clinically, antibodies targeting PD-1/PD-L1 reinvigorate the "exhausted" T cells in TME and show remarkable objective response and durable remission with acceptable toxicity profile in large numbers of tumors such as melanoma, lymphoma, and mismatch-repair deficient tumors. Nevertheless, most patients are still refractory to anti-PD-1/PD-L1 therapy. Identifying the predictive biomarkers and design rational PD-1-based combination therapy become the priorities in cancer immunotherapy. PD-L1 expression, cytotoxic T lymphocytes infiltration, and tumor mutation burden (TMB) are generally considered as the most important factors affecting the effectiveness of PD-1/PD-L1 blockade. The revolution in cancer immunotherapy achieved by PD-1/PD-L1 blockade offers the paradigm for scientific translation from bench to bedside. The next decades will without doubt witness the renaissance of immunotherapy.

Cell Identity and Spatial Distribution of PD-1/PD-L1 Blockade Responders

Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade

Investigating Mechanisms of Response or Resistance to Immune Checkpoint Inhibitors by Analyzing Cell-Cell Communications in Tumors Before and After Programmed Cell Death-1 (PD-1) Targeted Therapy: An Integrative Analysis Using Single-cell RNA and Bulk-RNA Sequencing Data

Immune Landscape and Therapeutic Strategies: New Insights into PD-L1 in Tumors

PD-1 regulation in immune homeostasis and immunotherapy

Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens

Investigating Cell-Cell Crosstalk in Pre- and Post- Programmed Cell Death-1 (PD-1) Targeted Therapy Tumours Using Single-Cell RNA-Sequencing Analysis

What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?

Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.

Non-canonical PD-1 signaling in cancer and its potential implications in clinic

Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways

Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors.

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PDL1 blockade

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

Application of PD-1 Blockade in Cancer Immunotherapy

PD-L1 on Host Cells is Essential for PD-L1 Blockade–mediated Tumor Regression

The Anticancer Immune Response of Anti-Pd-1/pd-l1 and the Genetic Determinants of Response to Anti-Pd-1/pd-l1 Antibodies in Cancer Patients

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression